Sinopharm Group Co. Ltd
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and healthcare products, and medical devices in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices Distribution, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical … Read more
Sinopharm Group Co. Ltd (X2S) - Total Liabilities
Latest total liabilities as of June 2025: €291.07 Billion EUR
Based on the latest financial reports, Sinopharm Group Co. Ltd (X2S) has total liabilities worth €291.07 Billion EUR as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Sinopharm Group Co. Ltd - Total Liabilities Trend (2013–2024)
This chart illustrates how Sinopharm Group Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Sinopharm Group Co. Ltd Competitors by Total Liabilities
The table below lists competitors of Sinopharm Group Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Yes Bank Limited
NSE:YESBANK
|
India | ₹3.63 Trillion |
|
Chandra Asri Petrochemical Tbk
JK:TPIA
|
Indonesia | Rp5.51 Billion |
|
Muthoot Finance Limited
NSE:MUTHOOTFIN
|
India | ₹1.44 Trillion |
|
Box Inc
NYSE:BOX
|
USA | $1.85 Billion |
|
Acer Incorporated
PINK:ACEYY
|
USA | $144.73 Billion |
|
CyberAgent Inc
F:CL2
|
Germany | €281.48 Billion |
|
Burberry Group plc
PINK:BBRYF
|
USA | $2.83 Billion |
Liability Composition Analysis (2013–2024)
This chart breaks down Sinopharm Group Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.34 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.63 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.69 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sinopharm Group Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sinopharm Group Co. Ltd (2013–2024)
The table below shows the annual total liabilities of Sinopharm Group Co. Ltd from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €266.14 Billion | +1.17% |
| 2023-12-31 | €263.08 Billion | +3.29% |
| 2022-12-31 | €254.71 Billion | +8.04% |
| 2021-12-31 | €235.76 Billion | +6.54% |
| 2020-12-31 | €221.29 Billion | +14.69% |
| 2019-12-31 | €192.95 Billion | +15.20% |
| 2018-12-31 | €167.50 Billion | +41.62% |
| 2017-12-31 | €118.27 Billion | +4.50% |
| 2016-12-31 | €113.18 Billion | +14.84% |
| 2015-12-31 | €98.55 Billion | +6.70% |
| 2014-12-31 | €92.37 Billion | +20.20% |
| 2013-12-31 | €76.84 Billion | -- |